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Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have
significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal
kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for
therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human
BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed
into phase III trials. However, additional research is necessary to identify the optimal dosing schedule, as well as
patients most likely to benefit from BTK inhibition. This review summarizes preclinical and clinical development
of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, and ONO-4059,
CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.Introduction
Identifying novel mediators that regulate the growth and
death of cancer cells has facilitated the development of
more effective anti-cancer agents that have revolutionized
treatment options and clinical outcomes in cancer pa-
tients [1-4]. For instance, rituximab, a first-in-class chimeric
monoclonal antibody (MoAb) targeting CD 20 molecule,
has had clear impact on response rates and survival out-
comes, and has become a standard component of treatment
regimens for many patients with B-cell non-Hodgkin’s
lymphomas (NHLs) [5-7]. MoAbs targeting CD 19 molecule
are also rapidly moving through clinical trials [8]. In recent
times, Bruton’s tyrosine kinase (BTK), a crucial terminal
kinase enzyme in the B-cell antigen receptor (BCR) signaling
pathway has emerged as a novel target [9]. This downstream
signal transduction protein is a critical effector molecule that
governs normal B-cell development, differentiation and func-
tioning, and has also been implicated in initiation, survival
and progression of mature B-cell lymphoproliferative
disorders [10].
Ibrutinib, a novel BTK-targeting inhibitor, has shown
significant activities across a variety of B-cell neoplastic* Correspondence: delong_liu@nymc.edu
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reproduction in any medium, provided the ordisorders and autoimmune diseases in preclinical models
and clinical trials [11]. However, additional research is ne-
cessary to identify the optimal dosing schedule, as well as
patients most likely to benefit from BTK inhibition. This
review provides a general overview of three main topics:
1) BTK signaling pathway in B-cell lymphopoiesis with
emphasis on its role in the pathogenetic mechanisms that
underlie B-cell lymphoproliferative disorders; 2) Novel
BTK inhibitors in preclinical and clinical development.
and 3) Preclinical models and clinical experiences with
ibrutinib and other BTK inhibitors in the treatment of
various B-cell disorders and autoimmune disorders.
BTK signaling pathway, B-cell lymphopoiesis, and
tumorigenesis
BTK, also known as agammaglobulinemia tyrosine kinase
(ATK) or B-cell progenitor kinase (BPK), is a non-receptor
tyrosine kinase that was initially identified as the defective
protein in human X-linked agammaglobulinemia (XLA)
[12,13]. The protein is predominantly expressed in B-
lymphocytes at various stages of development (except in
terminally differentiated plasma cells), and less commonly
in myeloid and erythroid progenitor cells [14]. It is encoded
by the XLA gene that maps to a 37 kb DNA fragment on
chromosome Xq22 [15,16]. BTK is a member of the Tec
family of protein tyrosine kinases. The Tec family has five
members and is the second largest family of cytoplasmic
tyrosine kinases. BTK has domains of pleckstrin homologyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Akinleye et al. Journal of Hematology & Oncology 2013, 6:59 Page 2 of 9
http://www.jhoonline.org/content/6/1/59(PH), Tec homology (TH), Src homology 3 (SH3), Src
homology 2 (SH2), and tyrosine kinase or Src homology 1
(TK or SH1) (Figure 1) [17]. The PH domain contains
the binding site for transcription factor BAP-135/TFII-I
[18], harbors the inhibitory segment for downregulators
such as PIN 1, IBTK (inhibitor of BTK) [19], and also
mediates BTK’s interaction with second messenger phos-
phatidylinositol 3,4,5-trisphosphates (PIP3) [20]. Adjacent
to the PH domain is a segment of 80 amino acid residues
denoted as the TH domain. The TH domain houses
conserved regions designated as BTK motif (zinc cofactor
binding site) and proline-rich stretch [21], and serves as a
major determinant binding site for protein kinase C-beta
(PKC-β) [22]. Initial activation (trans-phosphorylation)
of BTK takes place in the activation loop located in the
SH1/TK domain; however further activation occurs within
the SH3 and SH2 domains, which contains major auto-
phosphorylation sites [23,24]. These Src homologous
domains also contain the nuclear localization signals (NLS)
and nuclear export sequence (NES) required for nucleocyto-
plasmic shuttling of BTK [25]. In addition to the activa-
tion loop, the ATP binding site, the catalytic apparatus,
and the allosteric inhibitory segments are also situated
in the SH1/TK domain [26].
BTK functions downstream of multiple receptors in-
cluding growth factors, B-cell antigen, chemokine, and
innate immune receptors, and thereby initiates a diverse
range of cellular processes, such as cell proliferation,
survival, differentiation, motility, angiogenesis, cytokine
production, and antigen presentation [27-30]. In steady-
state conditions, BTK is predominantly cytosolic, un-
phosphorylated and catalytically inactive [20]. BTK acti-
vation is a complex process and a critical step in this
process requires translocation of BTK to the plasma
membrane [20].Figure 1 BTK structure. BTK belongs to the Tec family of protein tyrosine kina
SH3 (Src homology 3) SH2 (Src homology 2), and SH 1/TK (Src homology1/Tyro
upstream molecules are shown in the diagram.Upon engagement by their corresponding ligands, acti-
vated receptors recruit and phosphorylate intracellular
signal transducer enzyme, phosphatidylinositol 3-kinase
(PI3K), which then acts on membrane-bound phos-
phatidylinositol 4,5-bisphosphate (PIP2) to generate sec-
ond messenger phosphatidylinositol 3,4,5-trisphosphates
(PIP3) [20]. PIP3 binds to BTK’s PH domain and recruits
BTK to the plasma membrane, where BTK is initially
trans-phosphorylated at Tyr-551residue by Syk and Lyn
kinases [31]. BTK then undergoes autophosphorylation
reaction at Tyr-223 residue to become physiologically
active [24]. Activated BTK can interact with adapter
protein BLNK/SLP65 through its SH2 domain. The com-
plex can then activate phospholipase C (PLC)-γ2 [32],
triggering a cascade of events that culminates in sustained
intracellular calcium influx and indirect activation of
downstream transcriptional signaling such as MEK/ERK, p38
MAPK, and JNK/SAPK pathways (Figure 2) [27,28,33-35].
Other downstream substrates of BTK include transcrip-
tion factors BAP-135/TFII-I, NFκB, ARID3A, STAT3 and
NFAT, where BTK plays a critical role in direct transcrip-
tion regulation and the expression of hundreds of genes
[29,31,34,36]. Under certain physiological conditions, BTK
can translocate to the nucleus and activate the transcrip-
tion of specific target genes [25], but BTK itself does not
bind directly to the DNA.
PKC-β can directly phosphorylate BTK’s TH domain
at Ser-180, resulting in shuttling of BTK back to the
cytoplasmic compartment [22]. Interactions with PIN1,
SH3BP5, CAV1 and IBTK also lead to dramatic down-
regulation of the kinase activity of BTK [19,37-39].
BTK plays indispensable roles in B-cell lymphopoiesis.
It orchestrates orderly development and differentiation
of immature B-cells to mature forms through activation
of positive cell cycle regulators and differentiation factorsses and is composed of the PH (pleckstrin homology), TH (Tec homology),
sine kinase) domains. Binding sites for BTK substrates, inhibitors, and
Figure 2 BTK signaling pathway. BTK translocates to the plasma membrane by interacting with PIP3 to become membrane-bound where it
undergoes sequential activation through trans-phosphorylation by Lyn and Syk kinases, followed by autophosphorylation. The downstream
substrates of activated BTK and their associated signaling cascades are indicated.
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B-cells by regulating expression of pro- and anti-apoptotic
proteins [40-42].
Aberrant activation of the BTK-dependent pathways has
been implicated in maintaining malignant phenotype in a
wide variety of malignancies. Basal growth, survival, and
cancer progression in mature B-cell lymphoproliferative
disorders appear to be promoted by dysregulated BTK
activity [10,43,44]. Constitutive BTK activation repre-
sents an absolute prerequisite for CLL development and
enhances leukemogenesis in mouse models of CLL [45].
In addition, altered BCR-BTK signaling promotes cell
survival in the activated B-cell-like (ABC) subtype ofDLBCL [46]. Somatic gain-of-function mutations in BTK
have also been identified in colorectal carcinoma [47],
acute lymphoblastic leukemia (ALL) [48], and chronic
myeloid leukemia (CML) [49].BTK inhibitors (BTKi) in clinical trials and
preclinical development
Small molecules with BTK-inhibitory property have
emerged as promising therapeutic agents for the treat-
ment of hematological malignancies and autoimmune
disorders [50-52]. As such, a number of compounds,
such as ibrutinib, GDC-0834, HM-71224, CC-292, and
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development to clinical trials [http://clinicaltrials.gov].
Ibrutinib
Preclinical studies of ibrutinib
Ibrutinib (formerly PCI-32765) is an orally bioavailable,
first-in-class, highly potent small molecule inhibitor
with subnanomolar activity (IC50, 0.5 nM) against BTK
(Table 1) [11]. It selectively binds to Cys-481 residue in
the allosteric inhibitory segment of BTK (TK/SH1 domain),
and irreversibly blocks its enzymatic activity [53]. The
compound also abrogates the full activation of BTK by
inhibiting its autophosphorylation at Tyr-223 [11]. In-
vitro studies showed that ibrutinib induces dose- and
time-dependent cytotoxicity in CLL tumor cell lines via
activation of caspase-3 dependent apoptotic pathway [9].
Ibrutinib also inhibits DNA replication [54], suppresses
TLR signaling-mediated proliferation [9], and blocks
pro-survival pathways in CLL cells by downregulating
CCL3 and CCL4 expression [54]. More so, the com-
pound antagonizes BTK-dependent chemotaxis to CXCL12
and CXCL13 [55]. Ibrutinib interferes with proliferation
and survival in B-ALL cell lines including Ph+/BCR-ABL1
positive cells [56]. In a xenografted TCL1 mouse model
of CLL, ibrutinib dosed at 25 mg/kg/day delayed disease
progression [54]. In-vivo studies by Honigberg et al.
using MRL-Fas (lpr) lupus mouse models demonstrated
that ibrutinib-induced BTK inhibition is associated with
reduced autoantibody production and suppression of
kidney disease development [11].
Clinical trials of ibrutinib
Ibrutinib is highly efficacious and safe, and has now
entered phase III clinical trials for a variety of B-cell
neoplasms. In an initial, multi-institutional phase I dose-
escalating study, two dosing schedules of ibrutinib was
tested in patients with relapsed or refractory FL, SLL/CLL,Table 1 BTK Inhibitors in preclinical and clinical development
BTK inhibitor Stage of development
Ibrutinib Phase II/III CLL/SLL, M









NR not reported.MCL, MZL, DLBCL, and WM who had failed at least one
previous therapy [57]. Fifty-six patients received oral
ibrutinib at doses of 1.25, 2.5, 5, 8.3, or 12.5 mg/kg daily
on a 28 days on, 7 days off schedule (35-day cycle), or
continuous daily dosing of 8.3 mg/kg or 560 mg until
disease progression (PD) or unacceptable toxicity. After
a median of 5 cycles of treatment, only two dose-
limiting toxicities (DLTs) occurred and ibrutinib was
found to be safe and well tolerated. The most common
adverse effects were grade 1 or 2 non-hematologic
toxicities, which included rash, nausea, fatigue, diarrhea,
muscle spasms/myalgia and arthalgia. Hematologic toxic-
ities were less common, and included grade 3 to 4 neu-
tropenia (12.5%), thrombocytopenia (7.2%), and anemia
(7.1%). In CLL patients, ibrutinib treatment is character-
istically associated with rapid resolution of enlarged lymph
nodes along with a surge in peripheral blood lymphocytosis.
Of 50 patients evaluated for response, an overall response
rate (ORR) of 60% was achieved across all histological types
with the best efficacy demonstrated in patients with MCL
(78%) and SLL/CLL (79%). The responses lasted for at least
10 months. Notably, a median progression free survival
(PFS) of 13.6 months was also achieved [57]. Though
both intermittent and continuous dosing schedules dem-
onstrated similar efficacy and toxicity profiles, the study
favored continuous dosing for phase II studies due to
possibility of reversed biologic activity with intermittent
therapy.
Given the high efficacy of ibrutinib in the precedent
phase I study, a larger study was done to investigate the
activity of single-agent ibrutinib in 111 heavily-pretreated
patients with relapsed or refractory MCL [58]. Patients
received a daily dose of 560 mg orally in a continuous
28-day cycles until disease progression or unacceptable
toxicities. After a median follow-up of 15.3 months, the
ORR was 68% (21% CR, 47% PR) with median response
duration of 17.5 months, and was independent ofDisease(s) IC50 Reference
CL, WM, ABC-DLBCL, MM 0.5 nM [54,57,58,60]
umatoid Arthritis 5.9 nM [70,71]
atoid Arthritis, SLE 4.0 nM [72,73]
NR 400 nM [74]
umatoid Arthritis 1.9 nM [74]
umatoid Arthritis NR [75]
CLL/B-NHL < 0.5 nM [76-78]
CLL 2.2 nM [79]
ne Diseases, B-cell NHL < 1 nM [80]
B-cell NHL 17.2 μM [81-83]
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the median OS was not reached, the median PFS was
13.9 months. Based on these collective efficacy data,
ibrutinib was granted a ‘breakthrough therapy’ designa-
tion by the FDA in February 2013 for patients with
relapsed/refractory MCL, and a phase III registration trial
(RAY) of ibrutinib monotherapy versus temsirolimus has
been initiated in the same patient population.
Long-term tolerability and sustained antitumor activity
of ibrutinib in heavily pretreated patients with refractory/
relapsed FL have also been reported. Kunkel and col-
leagues showed that ibrutinib was well-tolerated and
active, with an ORR was 55% (3 CR) and median PFS
was 13.4 months [59]. Most common treatment-related
side effects were dry mouth, constipation and diarrhea.
Encouraging results from the phase I study in CLL pa-
tients prompted a phase Ib/II trial, where patients with
relapsed/refractory CLL/SLL (n=85), predominantly with
high-risk disease, received oral ibrutinib at either 420 mg
or 840 mg daily until disease progression or unacceptable
toxicity [60]. Tolerability profile was acceptable as most
adverse events were grade 1 or 2 diarrhea, fatigue, and
URI that resolved spontaneously. Higher drug discon-
tinuation rate occurred in the 840 mg cohort compared
with the 420 mg cohort (12% versus 4%). The ORR was
71% in both cohorts, and not dependent on clinical and
genomic risk factors (such as 17p deletion) present
before treatment. The characteristic drug-induced re-
distribution lymphocytosis that accompanies lymph node
reduction was observed generally by day 7, peaked at
median of 4 weeks of treatment, and then slowly declined.
The responses were durable with the estimated 26-month
PFS and OS rates being 75% and 83% respectively. Of note,
this study initially included thirty-one treatment-naïve CLL
patients older than 65 years, where ibrutinib was investi-
gated as an upfront therapy. After a median follow-up of
16.6 months, the overall response rate was 71% (CR 10%)
suggesting that ibrutinib could be a reasonable choice for
newly diagnosed elderly patients with CLL [61,62].
Patients’ enrollment is underway for two phase III
registration trials of single-agent ibrutinib in CLL/SLL
patients to further demonstrate its impact on clinical
outcomes. In RESONATE 1, ibrutinib is being compared
with ofatumumab in patients with relapsed/refractory CLL/
SLL, whereas RESONATE 2 is to investigate ibrutinib as
frontline therapy for newly diagnosed elderly patients
with CLL/SLL in comparison with chlorambucil. In-
terim analyses from these trials are expected during the
1st quarter 2014.
Updated interim results from an ongoing open label
phase II trial showed that ibrutinib is active in patients
with activated B cell-like (ABC) subtype of DLBCL har-
boring both CD79B and MYD88 L265P mutations [63].
Heavily pretreated patients (n=70) with relapsed/refractoryDLBCL received oral ibrutinib 560 mg daily until disease
progression or onset of unacceptable toxicities. The ORR
was significantly greater in patients with the ABC subtype
compared to those with the GCB subtype (41% versus 5%,
p=0.007), suggesting preferential antitumor activity in ABC
DLBCL. The median OS was 9.7 months for the ABC
subtype, compared to 3.35 months for the GCB sub-
type. Similarly, ibrutinib has potential antitumor activ-
ities in multiple myeloma (MM), targeting both tumor
cells and their supporting microenvironment. Vij and
colleagues reported early reductions in plasma levels
of growth factors (e.g. VEGF, EGF, and FGF), cytokines
(e.g. TNFα), chemokines (CCL3, CCL4, Groα), and markers
of bone turnover (e.g. sclerostin, RANKL) in patients with
relapsed/refractory MM treated with ibrutinib 420 mg
once daily [64].Clinical trials of ibrutinib in combination regimens
The promising results of single agent ibrutinib have led
investigators to explore its synergistic efficacy in com-
bination with established chemoimmunotherapy regimens
with the goal of enhancing and achieving durable re-
sponses. Treatment with ibrutinib plus ACY1215, a
selective histone deacetylase 6 (HDAC6) inhibitor, pro-
duced a direct synergistic antitumor effect in MCL tumor
cell lines accompanied by a 3-fold increase in induction of
apoptosis [65]. One of the first clinical studies addressing
this purpose was a phase II study that showed ibrutinib
plus rituximab (IR) was profoundly effective (ORR=85%),
and shortened the duration of re-distribution lymphocyto-
sis in CLL patients with high-risk features [66]. Adding
ibrutinib to BR (bendamustine and rituximab) appear to
produce a better clinical response (ORR=93%) than IR in
relapsed/refractory CLL patients [67]. In a recent report
of another ongoing phase Ib/II study, administration of
ibrutinib in combination with ofatumumab demonstrated
potent anti-leukemic activity and tolerable toxicity profile
in heavily-pretreated patients with relapsed/refractory
CLL/SLL [68]. Blum et al. also demonstrated excellent
response rates in MCL patients treated with a combin-
ation of ibrutinib plus rituximab and bendamustine
[69]. In light of these encouraging results, two phase III
trials are currently accruing participants to investigate
the combination of ibrutinib plus bendamustine and ri-
tuximab versus placebo plus bendamustine and rituximab
in subjects with newly diagnosed MCL (SHINE), as well
as in patients with refractory/relapsed CLL (HELIOS).
Additional preclinical experiments and clinical trials are
currently underway to further explore this strategy in
other B-cell disorders [NCT01829568, NCT01569750,
NCT01479842].
Given the current data, ibrutinib appears to be one of
the most active single agents for CLL/SLL and MCL.
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GDC-0834 is a potent, highly selective, reversible BTK
inhibitor with nanomolar activity in enzyme kinetics
studies. A carboxamide derivative, GDC-0834 is being
developed as a potential therapeutic agent for rheumatoid
arthritis (RA) [70]. The compound demonstrates effective
activity against BCR- and CD40-dependent B-cell prolifera-
tion and activation, and potently inhibits immune complex-
mediated inflammatory cytokine elaboration in monocytes.
In collagen-induced arthritis (CIA) rat models, treatment
with oral GDC-0834 dosed at 30-100 mg/kg demonstrated
robust anti-arthritis effect characterized by significant dose-
dependent reduction in ankle swelling, and accompanied
by potent inhibition of autophosphorylation of BTK [70].
Pharmacokinetics (PK) results of a recent phase I study of
GDC-0834 in healthy volunteers showed that the drug is
heavily metabolized by the liver to an inactive metabolite
via amide hydrolysis [71]. GDC-0834 is undergoing further
clinical development to assess its safety and tolerability in
patients with inflammatory arthritis.
RN-486
A potent and competitive small molecule with reversible
BTK-inhibitory property, RN-486 demonstrates sub-
nanomolar and highly specific activity against purified
BTK in enzymatic assays. It blocks BCR-mediated CD69
expression in B-cells in a dose-dependent manner. Pre-
clinical studies also showed that RN-486 efficiently in-
hibits FcR-mediated TNF-α production in monocytes,
and abrogates FcεR-mediated mast cell degranulation [72].
The anti-rheumatic potential of RN-486 has been investi-
gated in preclinical studies. In two murine models of RA,
the compound demonstrates potent anti-inflammatory
and disease-modifying effects characterized by reduction
in pannus formation, cartilage damage and bone resorption
[72]. It also abrogates type I and type III hypersensitivity
responses in rats. RN-486 suppresses IgG anti-dsDNA
secretion, blocks CD69 expression in response to BCR
crosslinking, and completely inhibits progression of glom-
erular nephritis in systemic lupus erythematosus (SLE)
prone NZB/W mouse models [73].
CGI-560
CGI-560, a benzamide derivative, is a highly selective
(>10 fold) but modestly potent small molecule inhibitor of
BTK with an IC50 of 400 nM in enzymology assays [74].
Optimization of CGI-560 property by medicinal chemistry
led to the discovery of another benzamide analogue (CGI-
1746) with exquisite potency and unique BTK-inhibitory
activity [74].
CGI-1746
An exquisitely selective and ATP-competitive small
molecule inhibitor with unique BTK-inhibitory property,CGI-1746 potently inhibits both auto- and trans-
phosphorylation of BTK. It binds and occupies an SH3
binding pocket within the un-phosphorylated BTK and
stabilizes it in this inactive enzyme conformation state
[74]. In cellular assays, the compound blocks BCR-mediated
B-cell proliferation and suppresses FcγRIII-induced TNFα,
IL-1β and IL-6 production in macrophages. CGI-1746
demonstrated robust anti-arthritic activity in experimen-
tal mouse models evident by diminished cytokine and
autoantibody levels in the joints [74].
HM-71224
HM-71224 is a novel, oral, small molecule BTK inhibitor
that is being developed by Hanmi pharmaceuticals [75].
The compound has progressed into phase I clinical testing,
and its PD, PK, safety, and tolerability are being assessed
in healthy volunteers in Korea and the Netherlands
[NCT01765478].
CC-292
CC-292 (formerly AVL-292) is an orally bioavailable acryl-
amide derivative with potent, irreversible anti-BTK activity
(IC50 <0.5 nM) in biochemical kinase assays. The small
molecule inhibitor abolishes BCR signaling in Ramos
human Burkitt's lymphoma cell line by covalently bind-
ing to BTK, and selectively inhibits its autophosphorylation
as well as activation of PLCγ2 and other downstream sub-
strates of BTK [76]. When dosed orally five times a week
for 6 weeks, CC-292 decreased tumor burden in pre-
clinical xenografts MM mouse models of human
Luc-GFP+-MM.1S myeloma cell line [77]. In established
CIA mouse models, treatment with CC-292 dosed at 3,
10 and 30 mg/kg produced dose-dependent resolution
of clinical signs and histopathologic features of inflam-
matory joint disease including reduction in joint swell-
ings and redness, and regression of pannus formation
[76]. Clinical progress has been seen with CC-292. In
normal healthy volunteers who received 2 mg/kg CC-292,
PK analysis showed that the compound was rapidly
absorbed, achieving peak plasma concentrations within
30–120 minutes, and demonstrating a median terminal
elimination half-life of 1.9 hours. Analysis of BTK activity
in same study subjects indicated that the drug remained
active for a prolonged duration after its plasma levels had
declined to undetectable levels [76]. Given these data, CC-
292 was advanced to phase Ib clinical testing in patients
with B-cell disorders. Updated results from a dose-finding
study of CC-292 in patients (n=86) with relapsed or re-
fractory CLL and B-NHL revealed that the agent was
generally well-tolerated at doses ranging from 125-1000
mg daily, and at 375 and 500 mg twice daily [78]. The
most common treatment-emergent adverse effects were
diarrhea, fatigue, headaches and muscle spasms. Three
DLTs including thrombocytopenia, pneumonitis, and altered
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for response, seventeen (34%) achieved PR. Multiple on-
going phase I studies are expected to provide additional
safety results on CC-292 as a single agent or combin-
ation with other agents in patients with a wide variety
of B-cell lymphoproliferative disorders [NCT01766583,
NCT01744626, NCT01732861].
ONO-4059
ONO-4059 is a highly selective, orally bioavailable in-
hibitor of BTK kinase activity with a potency (IC50) of
2.2 nM. The compound covalently binds to BTK, and
reversibly blocks BCR signaling and B-cell proliferation
and activation. Like CC-262, ONO-4059 demonstrated
therapeutic efficacy in a mouse CIA model by suppress-
ing generation of inflammatory chemokines and cyto-
kines including IL-6, IL-8, and TNFα by monocytes, and
accompanied by regression of cartilage erosion, bone
damage, and pannus formation [79]. The data indicate
that ONO-4059 may have a potential benefit for the
treatment of patients with RA. In view of its anti-
proliferative activity in B-cells, ONO-4059 has progressed
into phase I clinical trials in CLL/NHL patients with
relapsed/refractory disease.
CNX-774
CNX-774 is another orally available, small molecule
inhibitor with irreversible BTK-inhibitory property. CNX-
774 is highly selective for BTK, and forms a ligand-
directed covalent bond with the Cys-481 residue within
the ATP binding site of the enzyme. In biochemical and
cellular assays, CNX-774 demonstrates potent inhibitory
activity towards BTK with an IC50 of <1nM and 1-10nM
respectively [80]. The compound has progressed to ad-
vanced preclinical development and additional in-vitro
and in-vivo data are awaited.
LFM-A13
LFM-A13 is a novel, first-in-class, dual BTK/Polo-like ki-
nases (PLK) inhibitor with anti-proliferative, pro-apoptotic,
and chemosensitising effects in leukemia/lymphoma and
breast cancer cells [4,81,82]. A leflunomide metabolite
analogue, LFM-A13 binds favorably to the catalytic site
within the kinase domain of BTK, and exhibits an inhibi-
tory potency (IC50) of 17.2microM in cell-free kinase
assays [83]. The compound is highly selective for BTK,
and specifically inhibits cellular BTK activity in chicken
lymphoma B18.2 B-cells and human NALM-6 leukemic
pre-B cells in a dose-dependent fashion [83]. In human
Ph+ ALL-1 and NALM-6 pre-B ALL cell line, treatment
with LFM-A13 enhances the sensitivity of the cells to
both ceramide- and vincristine-induced apoptosis [83].
Dosed at levels ranging from 10 to 80 mg/kg, LFM-A13
was not toxic to xenografted murine leukemia model[81]. The compound down-regulates BTK signaling in
myeloma cells evident by reduced in vivo homing of
myeloma cells to bone, prevention of myeloma-induced
bone resorption, and moderate suppression of myeloma
growth in primary myeloma-bearing SCID-rab mice [84].
These preclinical data provide the rationale for future clin-
ical development of LFM-A13 as a new therapeutic agent
for B-cell lymphoproliferative disorders.
Conclusion and future directions
Ibrutinib, a novel BTK-targeting inhibitor, has shown
significant activities across a variety of B-cell neoplastic
disorders and autoimmune diseases in preclinical models
and clinical trials. The data from clinical trials on CLL
and mantle cell lymphoma are particularly encouraging.
Novel BTK inhibitors, GDC-0834, HM-71224, CC-292,
and ONO-4059, CNX-774, LFM-A13, are under active
preclinical and clinical investigation. Among these, LFM-
A13 represents a first-in-class dual BTK-PLK inhibitor.
These novel inhibitors will provide new targeted therapy
not only for B-cell lymphomas, but also for autoimmune
disorders. Further research into combination of novel
small molecule inhibitors against different signaling path-
ways as well as combination of these inhibitors with other
biological and biochemical compounds will likely enhance
their clinical efficacy [34,85].
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